InflaRx (IFRX) to Release Quarterly Earnings on Thursday

InflaRx (NASDAQ:IFRX) is expected to issue its quarterly earnings data before the market opens on Thursday, March 20th. Analysts expect the company to announce earnings of ($0.27) per share and revenue of $0.13 million for the quarter.

InflaRx Stock Performance

IFRX opened at $1.22 on Tuesday. The firm has a market cap of $81.90 million, a P/E ratio of -1.13 and a beta of 1.98. The firm has a 50-day moving average of $2.03 and a 200 day moving average of $1.91. InflaRx has a fifty-two week low of $1.13 and a fifty-two week high of $2.82.

Analysts Set New Price Targets

Separately, HC Wainwright reaffirmed a “buy” rating and set a $8.00 price objective on shares of InflaRx in a report on Friday, March 7th.

InflaRx Company Profile

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage.